Roundtable II: Cost concerns for rheumatoid arthritis treatment

Am J Manag Care. 1999 Sep;5(14 Suppl):S880-8.
No abstract available

Publication types

  • Congress

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use
  • Arthritis, Rheumatoid / economics*
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / therapy
  • Cost-Benefit Analysis
  • Cytokines / economics
  • Cytokines / therapeutic use
  • Decision Making
  • Drug Costs*
  • Health Services Accessibility
  • Humans
  • Infliximab
  • Insurance Coverage
  • Patient Selection
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • United States

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • Tumor Necrosis Factor-alpha
  • Infliximab